All In Biotech

NDA 020801 · Kenvue Brands

Pepcid Ac

Famotidine · Oral

Last checked: Nov 20, 2026Latest source record: Oct 29, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Sep 24, 1998

Approved uses

2

Original approval plus efficacy supplements

Registered trials

147

23 Phase 3, 15 recruiting

FAERS reports

84,069

56,178 serious, 8,060 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • PEPCID AC · FAMOTIDINE 20MG · TABLET, CHEWABLE, ORAL · Over-the-counter
  • PEPCID AC · FAMOTIDINE 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, CHEWABLE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Famotidine" as an intervention, any sponsor and status, largest first.

All 147 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea5,466
  • fatigue5,213
  • diarrhoea5,066
  • chronic kidney disease4,686
  • off label use4,350
  • drug ineffective4,121
  • dyspnoea4,001
  • headache3,740
  • acute kidney injury3,418
  • vomiting3,314
  • pain3,253
  • dizziness3,130

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004743
2005736
2006692
2007679
2008850
2009721
20101,023
20111,563
20121,933
20131,154
20141,431
20152,430
20162,920
20173,227
20184,565
20195,504
20206,624
20216,789
20227,276
20237,328
20248,572
20259,562
20267,743

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 566 on PubMed

Sponsor: Kenvue Brands

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.